Articles related to GVHD

Explore the latest insights into the complex pathophysiology of steroid-refractory cGVHD and the significant strides made in treatment options, including the impactful roles of ruxolitinib, belumosudil, and ibrutinib in enhancing patient outcomes.

In light of recent findings, CD24Fc emerges as a potential game-changer in preventing acute GVHD in HSCT patients, with a notable survival rate improvement to 96.2% for severe cases.

Recent studies have highlighted the effectiveness of ruxolitinib in managing steroid-refractory chronic graft-vs-host disease, showcasing a significant improvement in overall response rates and failure-free survival compared to standard therapies.